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mittee, if it occurs with CAS. This provides a level of safe- 
ty, which is similar to that adopted by prior randomized 
clinical trials evaluating the efficacy of CEA verus medical 
management), 4 Had Naylor and colleagues adopted sim- 
ilar safeguards, the occurrence of five strokes in seven 
interventional procedures, which limited and in fact 
"stopped" the trial, could have been avoided. Publication 
of their report serves only to undermine the importance of 
randomized clinical trial methodology, which is the only 
mechanism whereby Level I or II evidence will be derived. 
A preferred title for their manuscript might have been 
"Randomized study of carotid angioplasty and stenting 
versus carotid endarterectomy: a trial that never should 
have been started." 
As we approach a position of clinical equipoise s on 
these two alternatives in the management of symptomatic 
extracranial carotid occlusive disease, we wish to reassure 
the vascular surgical community about the safety precau- 
tions adopted by CREST. A well-designed clinical trial 
with appropriate safeguards will provide an efficacy assess- 
ment of these two procedures before clinicians consider 
expanded use of CAS. 
Robert W. Hobson II, MD, 
for the Executive Committee, CREST 
UMDNJ-New Jersey Medical School 
Newark, NJ 
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Reply 
We thank Dr Hobson for his letter regarding the 
Leicester Carotid Angioplasty Trial) Its somewhat per- 
sonal style and belated submission (14 months after pub- 
lication) suggest hat it has been motivated by an under- 
standable desire to publicize CREST at a time of concern 
about the clinical equipoise, performance, and interpreta- 
tion of randomized trials of endarterectomy versus angio- 
plasty. We are,.however, pleased to respond regarding the 
safety and generalizability of randomized trials. 
Dr Hobson states that the safety considerations in our 
trial were "unacceptable" and impfies that the intervention- 
ist had not received appropriate raining. The latter criticism 
is quite unfounded. In addition to visiting one of the 
aclmowledged experts on carotid stenting (Dr Mathias in 
Germany), Dr Bolia performed a series ofangioplasfies with- 
out complication before patients were randomized. At the 
time, there was no certification program anywhere in the 
world, and Dr Bolia's results exactly paralleled the excelent 
results reported in the 1992 overview of angioplasty out- 
comes) When all symptomatic patients were later random- 
ized within the trial, complications did occur. However, 
when the videos were critically reviewed, we were unable to 
identify any specific problem with technique. 
As in the forthcoming CREST study, the Leicester 
trial did incorporate "we-defined criteria" before random- 
ization was considered and had specified stopping rules 
according to established statistical methods that were 
overseen by an independent Data Monitoring Committee. 
We do, however, agree that the question of balancing safe- 
ty against compromising the statistical integrity of interim 
analyses is particularly difficult, especially in the era of 
individual versus collective ethics. Dr Hobson's letter 
implies an understandable move toward individual ethics 
(ie, the needs of the individual outweigh the needs of the 
many), but it remains an inescapable fact that multicenter 
randomized trials rely on collective thics to provide infor- 
mation that will truly predict overall clinical practice. This 
problem was specifically raised in the discussion section of 
our paper. 
All randomized trials undertake interim analyses, so 
that the Data Monitoring Committee can assess afety and 
efficacy. However, interim analyses increase the likelihood 
of a type I error, 3whereby "chance" rather than technique 
may be responsible for adverse vents. Accordingly, the 
group sequential method with a predetermined level of 
significance was used to balance the important issues of 
individual safety and chance in the performance of the 
study. Ironically, it remains the opinion of some that our 
trial was suspended prematurely with the results simply 
reflecting the effect of chance. While not having seen the 
CREST protocol, Dr Hobson seems to imply that 2+ 
adverse vents (within how many cases?) could lead to sus- 
pension of that investigator f om recruitment, despite the 
investigator's having fulfilled the criteria to participate. 
Alternatively, the prospect of the investigator receiving a
visit from the trial regulators will inevitably alter his or her 
clinical equipoise for future trial recruitment. I f this is 
true, there is the very real risk of introducing significant 
bias, thereby compromising statistical integrity and the 
generalizability of any results. Clearly there is no easy solu- 
tion to reconciling this most difficult of ethical problems. 
We consider the comment that our trial "should never 
have been started" smacks of shooting the messenger 
while not listening to the message. Generalizability still 
remains a problem for endarterectomy because outcomes 
are currently not as good as those in the international tri- 
als. 4 This could also be a problem for angioplasty. At pre- 
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sent, we know that angioplasty is feasible and will surely 
have a role in the future. However, to date, it has not 
been proved to be either beneficial or generalizable. 
Although some have reported astonishingly good results 
in personal series, we are not alone in having encountered 
major problems. Thus the tendency to merely ascribe 
adverse outcomes to "poor technique" or "learning curve 
difficulties" is too simplistic. The pioneers of angioplasty 
(death/stroke rate <1% in 123 patients 2) clearly encoun- 
tered no learning curve and instantly developed a tech- 
nique that was safer than diagnostic angiography alone! 
Even the Asymptomatic Carotid Atherosclerosis Study 
had an angiographic stroke rate of 1.2%fi It is worth bear- 
ing in mind that our interventionist had better results 
when referred highly selected cases. The role of angio- 
plasty for "all comers" remains uncertain, but we wish our 
colleagues in CREST a successful recruitment. 
Finally, we are confused as to the inclusion of refer- 
ence 4 in the opening sentence in the last paragraph. To 
our knowledge, nowhere in the Asymptomatic Carotid 
Atherosclerosis Study do the authors refer to a position of 
"clinical equipoise" between endarterectomy and angio- 
plasty in the management of symptomatic diseasefi 
A. Ross Naylor, MD 
P. R. F. Bell, MD 
Leicester Royal Infirmary 
Leicester, United Kingdom 
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Regarding " In situ replacement of  the aorta in a 
contaminated field with the infrarenal inferior vena 
cava" 
To the Editors: 
Ting and colleagues (J Vas Surg 1999;30:363-6) report 
a case of a 38-year-old man with a residual retroperitoneal 
testicular tumor compressing the inferior vena cava (IVC) 
and surrounding the aorta. Resection was attempted with 
curative intent. Intraoperative damage to the duodenum and 
aorta required resection of the fourth portion of the duode- 
num and infrarenal aortic replacement. Because of consider- 
able contamination, the authors elected to replace a 6-cm 
segment of the inffarenal aorta with the patient's infrarenal 
IVC as an autogenous graft. The IVC was not reconstruct- 
ed. The patient had symptoms of compartment syndrome 
intraoperatively that was treated with four-compartment fas- 
ciotomies. The authors believe the compartment syndrome 
was a resttlt of a prolonged clamp time of 3 hours. 
Subsequent skin grafting was needed to cover the fascioto- 
my sites. The tumor has recurred at 12 months. This is an 
important report because it shows that the IVC is capable of 
sustaining systemic arterial pressures at 1 year without 
aneurysmal degeneration r rupture and is resistant to con- 
tamination. However, it also raises a number of concerns. 
Computed tomography had clearly showed, preopera- 
tively, severe involvement ofthe aorta where a plane of demar- 
cation could not be identified between the aorta and the 
rumor. Therefore, the need for aortic resection a d recon- 
struction should have been anticipated. A preoperative ascu- 
lar consultation, rather than an intraoperative consultation 
when the problems had occurred, would have allowed for 
planning and quite likely reduced the aortic damping time, 
decreasing the risk of compartment syndrome. A saphenous 
spiral graft may have been constructed before aortic clamping, 
further decreasing ischemic time, and may have avoided 
potentially eaving tumor cells in the reconstructed aorta. This 
would have been the procedure of choice. 1The use of alter- 
nate grafts more resistant to infection should have been con- 
templated preoperatively. 
Pericardial heart valves have been shown to be more 
resistant o infection than prosthetic valves in patients 
with endocarditis, and arterial homografts have been 
successfully used in infections of the ascending aorta.2, a 
It is not known whether cryopreserved aortic homo- 
grafts or pericardial xenografts are more resistant o 
infection than IVC autografts, specifically in the pres- 
ence of arterial pressure, nor can it be anticipated over 
prolonged periods which one of these grafts will degen- 
erate faster and become aneurysmal. It is difficult to jus- 
tify the use of the IVC for aortic replacement in this sit- 
uation because no previous reports existed especially 
when the IVC was not reconstructed. Prosthetic 
replacement of  the IVC has been disappointing. 4 The 
vena cava has been previously reconstructed with peri- 
cardial xenografts in the experimental model and in 
humans with improved results and extended patency.5, 6 
Bovine pericardium is readily available in most centers, 
and a custom-made tubular graft takes only a few min- 
utes to constructfi Although it may have been used for 
aortic replacement, 7 the authors may not have wanted to 
expose a tubular pericardial xenograft o arterial pres- 
sure, but the IVC could have been reconstructed easily 
without the need for a second incision. 
The end point in the pathophysiology of compartment 
syndrome is the accumulation of fluid in the extravascular 
space resulting from reperfusion injury. It leads to capil- 
lary compression and necrosis. The increase in venous 
hydrostatic pressure by the ligation of the IVC may have 
